Cogent Biosciences Inc

COGTNASDAQ · USD
27.74USD-0.07 (-0.26%)
125

Cogent Biosciences Inc (COGT) Option Chain

Cogent Biosciences Inc trades at $27.74, down 0.26%, with an IV Rank of 84.52%. This is high versus the past year, and the company carries a market cap of $4,839M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $28.00 strike shows calls at $0.50 / $1.85 and puts at $0.45 / $2.70, both carrying about $1.24 of extrinsic value. The call has a 55.29% probability of expiring out of the money, and the put has 44.71%. Volume is heaviest on the $35.00 calls, at 10 contracts, and the $29.00 puts, at 2, as of Nov 18, 2026.

Read more

Tracking the COGT option chain helps you see every strike and expiry on Cogent Biosciences Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of COGT options activity at a glance. Use our scanner to monitor the COGT option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For COGT stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where COGT options are being actively traded, and where they are not.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
16.14001.091.740.854.8026.00-6.51—4.800.004.800083.86
33.82001.440.740.054.3027.00-2.910.051.400.000.73056266.18
55.291801.180.000.501.8528.00+0.680.452.700.261.3113344.71
74.67001.350.00—1.3529.00+4.281.152.651.260.64212725.33
88.05801.100.00—1.1030.00+7.871.653.002.260.06020911.95

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank84.52% High
  • Market cap (M$)4,839
  • 52 weeks high-36.41%
  • 52 weeks low5.50%
  • Analyst recommendationStrong Buy
    1.17
  • Target price$55.82
    101.23% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2027-02-16
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.50
  • EPS growth next 5 years—

As of Nov 18, 2026